Transcutaneous Electrical Nerve Stimulation in Chemotherapy Induced Peripheral Neuropathy in Patients With Stage I-III Early Stage Breast Cancer

Chemotherapy-Induced Peripheral Neuropathy Clinical Trial

Official title:

Single-Institution Trial Investigating the Effectiveness of Transcutaneous Electrical Nerve Stimulation (TENS) in Taxane Induced Peripheral Neuropathy (CIPN) in Patients With Early Stage Breast Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05368428
• Other study ID #: STUDY00003705
• Secondary ID: NCI-2022-01726ST
• Status: Recruiting
• Phase: N/A
• Start date: October 19, 2022
• Est. completion date: March 31, 2025

Study information

• Verified date: June 2023
• Source: Emory University
• Contact: Manali Bhave, MD
• Phone: 404-778-1900
• Email: manali.ajay.bhave[@]emory.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase II trial examines transcutaneous electrical nerve stimulation (TENS) in patients with stage I-III breast cancer with chemotherapy induced peripheral neuropathy. TENS is a procedure in which mild electric currents are applied to some areas of the skin to potentially improve neuropathy. This trial may help determine if TENS is feasible and effective for the treatment of peripheral neuropathy symptoms while on chemotherapy.

Description:

PRIMARY OBJECTIVE: I. To evaluate the feasibility of daily transcutaneous electrical nerve stimulation (TENS) by measuring participant adherence to TENS for two weeks. SECONDARY OBJECTIVES: I. To evaluate the change in patient reported outcome (PRO) measures of symptoms (e.g. pain, tingling, numbness) and functional impairment. II. To evaluate the change in objective measures of neuropathy over the study period through bedside monofilament testing. TERTIARY/EXPLORATORY OBJECTIVES: I. To collect data on the type and use frequency of non-TENS chemotherapy-induced peripheral neuropathy (CIPN) treatments (e.g. neuropathic agents and doses) both at baseline and over the duration of the trial (six weeks). II. To measure the number of chemotherapy dose-limiting events (dose reductions, delays, discontinuations) over the duration of the trial. OUTLINE: Patients undergo TENS therapy at home daily over 1 hour for 14 days in the absence of unacceptable toxicity.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 27
• Est. completion date: March 31, 2025
• Est. primary completion date: March 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Biopsy proven stage I-III breast cancer actively undergoing neoadjuvant or adjuvant chemotherapy regimen that contains paclitaxel or docetaxel.
• At least Common Terminology Criteria for Adverse Events (CTCAE) grade 1 CIPN in hands or feet attributed to taxane chemotherapy.
• Actively undergoing paclitaxel or docetaxel with plans to continue during the two-week TENS treatment.
• Age >= 18 years
• For females of child-bearing potential, negative serum or urine pregnancy test within 14 days prior to starting TENS
• Given the potential concern that TENS could induce uterine contractions or interfere with fetal cardiac conduction, female of child-bearing potential (FCBP) must have a negative serum or urine pregnancy test prior to starting therapy
• Female of childbearing potential (FCBP) must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of TENS treatment. Should a woman become pregnant or suspect she is pregnant during the two weeks of TENS, she should inform her treating physician immediately. A female of childbearing potential (FCBP) is a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
• Willingness and ability of the subject to comply with scheduled visits, TENS administration plan, other study procedures, and study restrictions.
• Evidence of a personally signed informed consent indicating that the subject has been informed of the procedures to be followed, the experimental nature of the therapy, alternatives, potential risks and discomforts, potential benefits, and other pertinent aspects of study participation
• Patients must have the psychological ability and general health that permits completion of the study requirements and required follow up
• Women of child bearing potential (FCBP) must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation.

Exclusion Criteria:

• Skin wounds, skin breakdown or edema at the site of TENS electrode pad placement
• History of epilepsy
• Implanted electronic device including a cardiac pacemaker, defibrillator, pain pump etc.
• Pre-existing neuropathy
• Prior exposure to neurotoxic chemotherapy
• Previous use of TENS for CIPN
• Prisoners or an adult who is unable to consent
• Pregnancy

Related Conditions & MeSH terms

• Anatomic Stage I Breast Cancer AJCC v8
• Anatomic Stage IA Breast Cancer AJCC v8
• Anatomic Stage IB Breast Cancer AJCC v8
• Anatomic Stage II Breast Cancer AJCC v8
• Anatomic Stage IIA Breast Cancer AJCC v8
• Anatomic Stage IIB Breast Cancer AJCC v8
• Anatomic Stage III Breast Cancer AJCC v8
• Anatomic Stage IIIA Breast Cancer AJCC v8
• Anatomic Stage IIIB Breast Cancer AJCC v8
• Anatomic Stage IIIC Breast Cancer AJCC v8
• Breast Neoplasms
• Chemotherapy-Induced Peripheral Neuropathy
• Early Stage Breast Carcinoma
• Peripheral Nervous System Diseases
• Prognostic Stage I Breast Cancer AJCC v8
• Prognostic Stage IA Breast Cancer AJCC v8
• Prognostic Stage IB Breast Cancer AJCC v8
• Prognostic Stage II Breast Cancer AJCC v8
• Prognostic Stage IIA Breast Cancer AJCC v8
• Prognostic Stage IIB Breast Cancer AJCC v8
• Prognostic Stage III Breast Cancer AJCC v8
• Prognostic Stage IIIA Breast Cancer AJCC v8
• Prognostic Stage IIIB Breast Cancer AJCC v8
• Prognostic Stage IIIC Breast Cancer AJCC v8

Intervention

Other:
• Transcutaneous Electrical Nerve Stimulation
Undergo TENS

Locations

Country	Name	City	State
United States	Emory Saint Joseph's Hospital	Atlanta	Georgia
United States	Emory University Hospital Midtown	Atlanta	Georgia
United States	Emory University/Winship Cancer Institute	Atlanta	Georgia

Sponsors (2)

Lead Sponsor	Collaborator
Emory University	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluate the Feasibility of Daily TENS by Measuring Participant Adherence to TENS for Two Weeks	Adherence for each trial participant will be calculated by summing the number of one-hour TENS sessions completed and dividing by 14 total treatments. Adherence for the cohort will be summarized descriptively using descriptive statistics.	Up to 2 weeks
Secondary	Change in Patient Reported Outcomes Measurement Information System 29 score	Change in Patient Reported Outcomes Measurement Information System 29 score at two and six weeks compared to baseline; Physical Function scored on a scale from "without any difficulty" (maximum value) to "unable to do" (minimum value); Anxiety scored on a scale from "always" (maximum value) to "never" (minimum value); Depression scored on a scale from "always"(maximum value) to "never" (minimum value); Fatigue scored on a scale of "very much" (maximum value) to "not at all" (minimum value); Sleep Disturbance scored on a scale from "very good" (maximum value) to "very poor" (minimum value); Ability to Participate in Social Roles and Activities" scored on a scale from "never" (maximum value) to "always" (minimum value); Pain Interference scored on a scale from "very much" (maximum value) to "not at all" (minimum value); Pain Intensity scored on a scale of 0-10, where "10" is the maximum value and "0" is the minimum value.	At baseline and 2 and 6 weeks
Secondary	Change in Monofilament Testing	Testing at two and six weeks compared to baseline.	At baseline and 2 and 6 weeks